In this paper, co-authored with Professor Mike McNamee from Swansea University, we address the question whether it can be ethically justifiable to seek gene transfer to raise one’s own tolerance to pain in a therapeutic and in an elite sports context. As a case study we analyse a currently recruiting Phase 1 study that seeks to transfer Vascular Endothelial Growth Factor to treat pain in patients with peripheral artery disease, but that could plausibly be applied also in an elite sports context. We presented this paper at the International Association for Philosophy of Sport, Porto, Sept 12-15, 2012.
Camporesi S, McNamee MJ (2012) ‘Gene Transfer for Pain: A tool to cope with the intractable, or an unethical endurance-enhancing technology?’ Life Sciences, Society & Policy Journal 8: 20-31 doi:10.1186/1746-5354-8-1-20
You can read the full paper free of charge here.